The new CVON HBC-crossroads (HBCx) programme further builds on the central hypothesis that hemodynamic
changes are an important and potentially reversible cause of VCI, now taking a more multidimensional (i.e.
crossroads) approach to hemodynamics, also addressing flow regulation and variability and factors that
modulate the impact of hemodynamic disturbances in VCI.
We will evaluate the role of hemodynamics in VCI in:
● key cardiac conditions (atrial fibrillation, valvular disease, heart failure/venous congestion)
● vascular factors (blood pressure variability, vascular reactivity, endothelial (dys)function)
● the primary cerebral co-morbidity of VCI, amyloid pathology (i.e. assess interplay hemodynamics and
We will also address age, sex, and environment as modulating factors.
Our ambitions are to identify treatable targets, further improve the diagnostic protocols and analyses, translate
research tools to diagnostic applications, and provide integrated heart-brain care for patients.
The framework of HBCx includes mechanistic studies, proof of concept treatment studies targeting
hemodynamics, and the implementation of the HBC concept in heart-brain clinics in daily care. We will build
on the rich HBC1 dataset, refine the analyses and will also establish new cohorts and link up with other existing
cohort studies such as RACE-V. We foster our young talents, connect with other research consortia and
industrial partners, and involve patients and clinicians.
Participating centers are Amsterdam UMC (Dorien Hermkens, Pathology AMC; Ronak Delewi and Jan Piek, Cardiology, AMC; Bert van Rossum and Marco Gotte VUmc; Wiesje van der Flier and Astrid Hooghiemstra Alzheimercenter VUmc, Majon Muller, Internal Medicine VUmc), UMC Utrecht, Erasmus MC, Leiden UMC, Maastricht UMC and UMC Groningen. PI’s are Mat Daemen (Amsterdam UMC) and Geert Jan Biessels (UMCU).